This development places National Stem Cell in the sector for Anti-aging products and services, presently a $30 Billion Market, and one of the
Biggest Marketing Opportunities in the U.S. Today
MOUNTAINSIDE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC Bulletin Board: NHGI - News) today announced that it is currently in final stage negotiations to exclusively license one of its recently discovered biomaterials which holds promise as an effective anti- aging agent and treatment.
This biomaterial appears to promote the skin's natural ability to maintain youthful tone, texture and viscoelasticity. It is one of a group of recently discovered biomaterials, derived from the company's stem cell and progenitor cell lines, that may stimulate a variety of naturally occurring physiological mechanisms that are involved with the skins ability to preserve and repair itself. This group of biomaterials, for which a provisional patent has recently been filed, also holds promise for a broader and more intensive range of applications such as tissue repair for wound care.
Anti-aging is presently a $30 billion market and arguably, one of the biggest market opportunities in the U.S. today. In the next three years, it is expected to grow to $70 billion. There are 75 million Baby Boomers in the U.S. with 53 million between the ages of 40 and 50, according to Government Accounting Office. Every day 11,000 Baby Boomers turn 50 and this trend will continue for the next 10 years.. By 2012, 50 percent of the population will be over age 50; People over 50 years of age control 70 percent of the financial assets in the USA and 50 percent of all discretionary income.
National Stem Cell Holding, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. In addition to its work with stem cell therapeutics, the Company is also working to leverage its commercial infrastructure and product development capabilities of its wholly-owned subsidiary The Sperm Bank of NY. The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company is headquartered in Mountainside, NJ. For more information, please visit http://www.nationalstemcell.com.
"Safe Harbor Statement" Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2005, the Company's Quarterly Report on Form 10-QSB for the first quarter ended March 31, 2006. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.
|SOURCE National Stem Cell Holding, Inc.|
Copyright©2007 PR Newswire.
All rights reserved